The National Development and Reform Commission announced that in 2017 medical equipment revenue, profit ...

On March 27th, March 26, the Department of Industrial Coordination of the National Development and Reform Commission issued the "Analysis of the 2017 Economic Operation of the Pharmaceutical Industry." This should be the first analysis of the pharmaceutical industry operation released by the National Development and Reform Commission after the State Council's institutional reform. In the middle, we can also see that in the field of medical equipment, sanitary materials, or equipment, equipment manufacturing, whether it is the main revenue growth, or profit growth, and import and export growth, the data are not ranked first in the sub-miniature industry. The overall growth rate is not high.

In 2017, the development trend of the pharmaceutical industry as a whole was positive. The main business income, total foreign trade, total profit maintained a rapid growth, and the main business income was restored to double-digit growth, while maintaining supply, steady growth, and adjusting the structure. Other aspects have played an important role.

2017, above-scale medicine enterprise The main business income was 298.62 billion yuan, a year-on-year increase of 12.2%. The growth rate was 2.3 percentage points higher than that in 2016, and the double-digit growth was restored. The growth rate of main business income in the eight sub-industries is shown in the table below, among which the fastest-growing Chinese medicine decoction pieces Processing Industry and Chemistry drug API manufacturing.

2017 year pharmaceutical industry molecular industry main business income

The investment completed in 2017 was 598.63 billion yuan, a year-on-year decrease of 3.0%, which was 7.8 percentage points lower than the growth rate of industrial fixed asset investment during the same period. In recent years, the new version of GMP certification for pharmaceuticals is nearing completion, consistency evaluation, etc. product quality The promotion work is accelerated and some companies choose to abandon some of the varieties, projects, or delay the project construction of the varieties under evaluation, which will have a certain impact on the investment in fixed assets.

At the same time, with medicine The adjustment of industrial structure continued to deepen. In 2017, the total profits of enterprises above designated size achieved 351.97 billion yuan, an increase of 16.6% year-on-year, and a 1.0 percentage point increase in growth rate.

The profit growth rate was higher than that of the main business, and the overall profitability of the industry was improved. The profit growth of the eight sub-sectors is shown in the table below. The fastest-growing are the bio-pharmaceutical manufacturing and chemical formulation manufacturing industries, and the momentum of industrial development continues to increase. Added value product transfer.

Total profit of the pharmaceutical industry in 2017

According to the import and export data of the customs, in 2017, the total import and export trade volume of China's pharmaceutical products was US$116.68 billion, up 12.6% year-on-year; the import value was US$55.88 billion, an increase of 16.3% year-on-year; the export value was US$60.80 billion, an increase of 9.4% year-on-year. The highest value for five years.

The trade surplus was 4.92 billion U.S. dollars, a year-on-year decrease of 34.6%. Imports and exports both showed rapid growth. On the one hand, the growing health needs of the people drove imports of pharmaceutical products. Meanwhile, local companies continued to promote supply-side reforms, and the acceleration of the internationalization process also took. The rapid growth of exports has reversed the decline in exports in 2016.

2017 pharmaceutical product import and export structure statistics

The investment in pharmaceutical innovation continued to grow. On the one hand, the policy of “major new drug creation” major science and technology projects, and the three-year action plan on the enhancement of core competitiveness continued to increase support for pharmaceutical innovation, R&D, and industrialization of innovation achievements. On the other hand, a number of R&D projects have emerged. The industry leaders with large investment and significant innovation results, According to the annual reports of listed companies, R&D investment by Hengrui, Fosun, and Hisun etc. has reached about 10% of sales revenue, a large amount of capital has poured into the field of pharmaceutical innovation, a group of innovative growth The smooth financing of enterprises effectively promoted high-risk, long-period innovative drug research.

At the same time, with the continuous deepening of the review and approval reforms, medical instruments A series of measures such as the review and approval of approvals, the piloting of drug marketing license holders, and the optimization of review and approval batch processes have been rapidly implemented, greatly improving the efficiency of review and approval approval, and significantly improving the pharmaceutical innovation environment.

In 2017, our country independently developed R&D, the “Ebola virus disease vaccine” with completely independent intellectual property rights was granted the first approval in the world, bortezomib, tetanovir disoproxil fumarate, parecoxib sodium, Cappfifene, lenalidomide, teriparatide and other batches of heavy-duty first-innovation varieties and interventional prosthetic heart valves and other innovative medical device products have been approved for listing, continuously filling domestic gaps in various fields and improving the use of drugs for the people. Accessibility plays an important role in reducing the burden of disease.